Across 384 deduplicated European breast cancer trial codes authorized from 2024 to 2026, 174 listed at least one CRO or CRO-like operational vendor, equal to 45.3% of trials. CRO use rises most clearly once trials become multi-country, multi-site and high-enrolment programs. The clearest practical inflection appears at 4+ countries, 10+ sites or 300+ planned participants.
Across 384 deduplicated European breast cancer trial codes authorized from 2024 to 2026, 174 listed at least one CRO or CRO-like operational vendor, equal to 45.3% of trials. CRO use was highest in 2025 at 48 of 79 trials (60.8%), compared with 108 of 236 in 2024 (45.8%) and 18 of 69 in 2026 (26.1%).
CRO use is not simply a year effect. The stronger signal is operational scale: broader country coverage, higher site count, larger planned enrolment and heavier third-party vendor stacks.
CRO use increases with later development stage. Phase III breast cancer trials show the highest CRO rate, with 68 of 135 trials supported by CROs (50.4%). Phase II followed at 70 of 154 trials (45.5%), while Phase I was 36 of 95 trials (37.9%).
Phase III is the highest-CRO segment, consistent with larger geography, central laboratories, imaging, ePRO, recruitment vendors, depot logistics and monitoring load.
The strongest operational threshold is geography. CRO use is 28.8% in single-country trials, but rises to 57.1% once a breast cancer study spans 4–7 countries and 63.2% above 8 countries.
The country-count inflection appears at 4+ countries. CRO use increases from 28.8% in single-country studies to 57.1% in 4–7 country studies.
Site count also predicts CRO use. The CRO-use rate more than doubles between 1–3 site trials and 10–24 site trials. Above 25 sites, CRO support becomes the default operating model.
The practical site-count threshold starts around 10 sites. CRO use rises from 42.4% in 4–9 site trials to 56.1% in 10–24 site trials and 63.4% in trials with 25 or more sites.
The planned-enrolment inflection is especially clear. CRO use is 27.9% below 100 participants, 59.8% at 300–799 participants and 77.6% once planned enrolment exceeds 800 participants.
Planned enrolment is a strong CRO predictor in this breast cancer cohort. The clearest practical threshold begins at 300+ planned patients, where CRO use rises from 41.9% in the 100–299 patient band to 59.8% in the 300–799 patient band.
The most frequent CRO and CRO-like operational groups are global full-service CROs, central laboratory vendors, eCOA/ePRO providers, depot/logistics providers, imaging vendors and recruitment-retention specialists.
| CRO / vendor group | Trial appearances |
|---|---|
| IQVIA group | 31 |
| Labcorp group | 24 |
| Almac group | 23 |
| Parexel | 19 |
| ICON group | 18 |
| Fortrea | 13 |
| Syneos Health | 12 |
Breast cancer outsourcing is not limited to one full-service CRO model. The recurring pattern is a layered vendor stack combining CRO operations, central laboratory, ePRO, imaging, IRT, depot and recruitment functions.
IQVIA, Labcorp, Almac, Parexel, ICON and Fortrea appear across multiple authorization years, indicating recurring use in breast cancer programs rather than one-off outsourcing. The most persistent pattern is a layered execution stack rather than a single-vendor monopoly.
CRO-supported breast cancer trials were materially larger by country count, site count, planned participants and recruitment window. Mean country count was 5.8 in CRO-supported trials versus 2.4 in trials without CRO support. Mean site count was 23.6 versus 8.3, and mean planned participants were 512 versus 148.
| Metric | CRO-supported | No CRO listed |
|---|---|---|
| Mean countries per trial | 5.8 | 2.4 |
| Mean sites per trial | 23.6 | 8.3 |
| Mean planned participants | 512 | 148 |
| Mean recruitment window | 74 months | 48 months |
CRO support is a marker of execution scale. CRO-backed breast cancer trials are larger, longer and more operationally distributed.
CRO-supported breast cancer trial activity is concentrated in the large oncology-recruitment markets used for pan-European programs. Spain led with 285 CRO-supported sites and 6,940 CRO-supported participants, followed by Germany, France, Italy and Poland.
| Country | CRO-supported sites | CRO-supported participants |
|---|---|---|
| Spain | 285 | 6,940 |
| Germany | 242 | 6,100 |
| France | 221 | 5,870 |
| Italy | 198 | 5,220 |
| Poland | 150 | 3,900 |
CRO-supported breast cancer execution concentrates in large oncology-recruitment markets, led by Spain, Germany, France, Italy and Poland.
Swiss and US sponsors show the highest CRO reliance, consistent with cross-border sponsor execution, large Phase III portfolios and vendor-heavy centralized operations. Academic and local European sponsors show lower CRO use unless the trial becomes multinational or late-stage.
| Sponsor country | CRO trials | CRO reliance |
|---|---|---|
| Switzerland | 44/57 | 77.2% |
| United States | 37/49 | 75.5% |
| United Kingdom | 14/24 | 58.3% |
| Germany | 29/73 | 39.7% |
| Spain | 13/46 | 28.3% |
CRO-supported breast cancer trials are materially more vendor-heavy. Trials without CRO support average 1.9 third parties, while CRO-supported trials average 8.4. Among trials listing 10 or more third parties, 68.5% also list CRO support.
Vendor load is one of the clearest operational markers of CRO-supported execution. CRO-supported trials average more than four times as many third parties as trials without CRO support.
For European breast cancer trials, CRO use is not random. It is a marker of operational scale. The best predictors are not simply year or phase, but the practical execution burden created by geography, site count, planned enrolment and vendor stack.
The clearest threshold is reached at 4+ countries, 10+ sites or 300+ planned patients. Below those levels, many sponsor-led or academic breast cancer studies remain internally managed. Above those levels, the probability of CRO support rises sharply because sponsors need distributed monitoring, multilingual document handling, central services, enrolment infrastructure, IRT, ePRO, imaging, biospecimen logistics and country-level start-up execution.
CRO means contract research organization. A CRO-supported trial is a trial whose sponsor record lists at least one CRO or operational vendor performing delegated trial duties.
Country-count band means the number of European countries listed for trial conduct in the CTIS geography record. Site-count band means the total number of listed clinical sites across participating countries.
Patient-count band means planned participants from recruitment or country-level participant fields. Vendor-heavy trial means a trial with a larger third-party operational stack, including CROs, central laboratories, imaging vendors, IRT/ePRO providers, depot/logistics providers, recruitment vendors and specialist service providers.